# Visudyne® in Occult (VIO)

> **NCT00121407** · PHASE3 · COMPLETED · sponsor: **QLT Inc.** · enrollment: 364 (—)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Visudyne for injection

## Key facts

- **NCT ID:** NCT00121407
- **Lead sponsor:** QLT Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 364 (—)
- **Last updated:** 2005-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121407, "Visudyne® in Occult (VIO)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00121407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*